161 related articles for article (PubMed ID: 17049817)
1. The need for accuracy in performing vancomycin intermediate resistant Staphylococcus aureus (VISA) and hetero--VISA detection methods.
Wootton M
Int J Antimicrob Agents; 2006 Dec; 28(6):586. PubMed ID: 17049817
[No Abstract] [Full Text] [Related]
2. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore.
Sng LH; Koh TH; Wang GC; Hsu LY; Kapi M; Hiramatsu K
Int J Antimicrob Agents; 2005 Feb; 25(2):177-9. PubMed ID: 15664490
[No Abstract] [Full Text] [Related]
3. [Detection methods for drug-resistant bacteria in routine examination--VISA].
Kinoshita S; Nakamachi Y
Rinsho Byori; 2000 Jan; Suppl 111():69-74. PubMed ID: 10804795
[TBL] [Abstract][Full Text] [Related]
4. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Appelbaum PC
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.
Walsh TR; Bolmström A; Qwärnström A; Ho P; Wootton M; Howe RA; MacGowan AP; Diekema D
J Clin Microbiol; 2001 Jul; 39(7):2439-44. PubMed ID: 11427551
[TBL] [Abstract][Full Text] [Related]
6. Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test.
Tajima Y; Komatsu M; Ito T; Hiramatsu K
J Microbiol Methods; 2007 Sep; 70(3):434-41. PubMed ID: 17655957
[TBL] [Abstract][Full Text] [Related]
7. Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains.
Drummelsmith J; Winstall E; Bergeron MG; Poirier GG; Ouellette M
J Proteome Res; 2007 Dec; 6(12):4690-702. PubMed ID: 17997515
[TBL] [Abstract][Full Text] [Related]
8. Detection of vancomycin-intermediate Staphylococcus aureus with the updated Trek-Sensititre System and the MicroScan System. Comparison with results from the conventional Etest and CLSI standardized MIC methods.
Nadarajah R; Post LR; Liu C; Miller SA; Sahm DF; Brooks GF
Am J Clin Pathol; 2010 Jun; 133(6):844-8. PubMed ID: 20472841
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of laboratory-generated vancomycin intermediate resistant Staphylococcus aureus strains.
Bhateja P; Purnapatre K; Dube S; Fatma T; Rattan A
Int J Antimicrob Agents; 2006 Mar; 27(3):201-11. PubMed ID: 16417988
[TBL] [Abstract][Full Text] [Related]
10. Rapid detection of vancomycin-non-susceptible Staphylococcus aureus using the spiral gradient endpoint technique.
Doddangoudar VC; O'Donoghue MM; Boost MV; Tsang DN; Appelbaum PC
J Antimicrob Chemother; 2010 Nov; 65(11):2368-72. PubMed ID: 20851816
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus.
Rose WE; Knier RM; Hutson PR
J Antimicrob Chemother; 2010 Oct; 65(10):2149-54. PubMed ID: 20693174
[TBL] [Abstract][Full Text] [Related]
12. Unacceptable performance and the lack of reproducibility results in the report of colorimetric methods for early detection of vancomycin and oxacillin resistance in Staphylococcus aureus.
Acuner IC; Eroglu C
J Clin Microbiol; 2006 Jun; 44(6):2318-9; author reply 2319. PubMed ID: 16757653
[No Abstract] [Full Text] [Related]
13. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
Howden BP
Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin-resistant Staphylococcus aureus in the clinic: not quite armageddon.
Bush K
Clin Infect Dis; 2004 Apr; 38(8):1056-7. PubMed ID: 15095206
[No Abstract] [Full Text] [Related]
15. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
[TBL] [Abstract][Full Text] [Related]
16. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.
Kosowska-Shick K; Ednie LM; McGhee P; Smith K; Todd CD; Wehler A; Appelbaum PC
Antimicrob Agents Chemother; 2008 Dec; 52(12):4510-3. PubMed ID: 18838583
[TBL] [Abstract][Full Text] [Related]
17. Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience.
Marlowe EM; Cohen MD; Hindler JF; Ward KW; Bruckner DA
J Clin Microbiol; 2001 Jul; 39(7):2637-9. PubMed ID: 11427582
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
19. hVISA/VISA: diagnostic and therapeutic problems.
Szabó J
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):1-3. PubMed ID: 19622051
[No Abstract] [Full Text] [Related]
20. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
